Movement Alert｜INNOVENT BIO Falls 3.07% in Regular Trading, Biotech Sector Under Pressure

Market Focus10:13

On October 7, INNOVENT BIO fell 3.07% in regular trading, trading at 96.3 Hong Kong dollars per share, with turnover of 160 million Hong Kong dollars.

Within the Biotechnology sector where INNOVENT BIO belongs, overall sector performance is weak. Among individual stocks, AKESO fell 3.35%, METIS TECHBIO-P fell 7.34%, BEONE MEDICINES fell 1.36%, 3SBIO fell 4.12%, and CANSINOBIO fell 7.39%.

INNOVENT BIO is an investment holding company primarily engaged in the research, development, production and sale of innovative drugs for major diseases such as oncology, cardiovascular and metabolic (CVM), autoimmune and ophthalmology. Drug formats include monoclonal antibodies, multi-specific antibodies, immune cytokines, antibody-drug conjugates (ADC), cell therapy and small molecule drugs. Its main products include Tyvyt (sintilimab injection), Bevacizumab injection, adalimumab injection, rituximab injection, and Pemazyre (pemigatinib tablets). The company operates primarily in domestic and overseas markets.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment